Alerta COFEPRIS: falsificacin y uso indebido La Comisin Federal para la Proteccin contra Riesgos Sanitarios (COFEPRIS) ha emitido alertas sobre la falsificacin de productos GLP-1
A notable correlation between low MT1B, MT1H, or MT1L expression and an increased risk of adverse outcomes was identified
Combination Therapy Often, the best results are achieved through a combination of treatments
Riboflavin kinase couples TNF receptor 1 to NADPH oxidase
As demand increases, our commitment to striking a balance between appropriate access and cost management remains our guiding principle
jamanetwork.com/journals/jamap : JAMA Psychiatry study highlights (semaglutide in schizophrenia spectrum disorders): Studied adults with schizophrenia spectrum disorders treated with clozapine or olanzapine, two antipsychotics strongly linked to weight gain and metabolic syndrome Participants were randomized to receive semaglutide (GLP-1 receptor agonist) vs placebo, in addition to usual psychiatric care Significant weight loss was observed in the semaglutide group compared with placebo Improved glycemic control including reductions in HbA1c and fasting glucose, even in early metabolic dysregulation Beneficial effects seen early, suggesting potential for prevention of diabetes rather than late treatment Semaglutide was generally well tolerated, with no worsening of psychotic symptoms Addresses a major unmet need, people with serious mental illness die earlier largely due to cardiometabolic disease Supports the role of GLP-1 receptor agonists as an adjunct treatment to mitigate antipsychotic-induced metabolic harm Bottom line: A promising strategy to reduce weight, diabetes risk, and long-term cardiovascular mortality in patients on high-risk antipsychotics
